
Seastar Medical Holding Corporation (($ICU)) has held its Q3 earnings call. Read on for the main highlights of the call. SeaStar Medical’s earnings call carried a broadly positive tone, led
Compare up to 40 stocks
Compared Stocks: 1 / 40
| Ticker | Company Name | Price | Change | % Change | |
|---|---|---|---|---|---|
| ICU | SeaStar Medical Holding | 1.05 | -2.08 | -66.45% |
| Name | Price | % Change | |
|---|---|---|---|
| $1.05 | -66.45% |

Seastar Medical Holding Corporation (($ICU)) has held its Q3 earnings call. Read on for the main highlights of the call. SeaStar Medical’s earnings call carried a broadly positive tone, led

Seastar Medical Holding Corporation (ICU) is scheduled to report 3rd quarter earnings on 11/11/2026, after the market closes. Regarding Q3 estimates, Wall Street analysts expect Seastar Medical Holding Corporation to

SeaStar Medical Holding ( ($ICU) ) has provided an announcement. SeaStar Medical Holding is a commercial-stage healthcare company focused on transformational treatments for critically ill patients facing organ failure and

SeaStar Medical (ICU) announced the Center for Biologics Evaluation and Research, or CBER, of the FDA has determined that the Quelimmune Pediatric SAVE Surveillance Registry has fulfilled the post-approval study

This filing relates to the offer and sale from time to time by the selling stockholders of up to 1.77M shares of common stock. The company is not selling any

SeaStar Medical (ICU) announced new data from the late-breaking presentation at ASN Kidney Week 2026 in Denver, Colorado. The late-breaking poster, titled “Improved Outcomes in Pediatric Sepsis-Associated AKI: Comparison of

SeaStar Medical (ICU) announced that the FDA has granted SeaStar Medical Breakthrough Device Designation for its Selective Cytopheretic Device, or SCD, therapy for the treatment of hyperinflammation in adult patients

An announcement from SeaStar Medical Holding ( ($ICU) ) is now available. On October 2, 2026, SeaStar Medical Holding Corporation entered into agreements with holders of outstanding warrants, prompting the

SeaStar Medical (ICU) announced that effective October 1, 2026, new ICD-10-PCS codes are available to enable administrative, billing, and statistical reporting for the use of SeaStar Medical’s SCD therapy in

Seastar Medical Holding Corporation (($ICU)) has held its Q2 earnings call. Read on for the main highlights of the call. SeaStar Medical’s latest earnings call struck a cautiously optimistic tone.
| Name | Analyst | Analyst Firm | Rating | Analyst Price Target | Action | Date |
|---|---|---|---|---|---|---|
| buy | Reiterated | May 14, 2026 |
| Name | Upcoming Earnings Date | Market Cap | EPS Forecast | Sales Forecast | PEG Ratio | P/E Ratio |
|---|---|---|---|---|---|---|
| Apr 1, 2027TBA | $4.15M | $-0.93 | $439.00K | 0.00 | -0.28 |
Compare Stocks Side-by-Side
Our stock comparison tool allows investors to compare multiple stocks simultaneously, providing comprehensive insights into key metrics, financial data, and analyst ratings. Make informed investment decisions by analyzing stocks side by side.
Key Features of Our Stock Comparison
How to Use the Stock Comparison Tool
Simply enter the ticker symbols of the stocks you want to compare in the search box above. You can add up to 40 stocks at once. The tool will automatically populate comparison tables with the latest data, allowing you to analyze and contrast different investment opportunities across various sectors and industries.
Popular Stock Comparisons
Investors frequently compare stocks within the same sector to identify the best investment opportunities. Popular comparisons include tech giants like Apple (AAPL) vs. Microsoft (MSFT), semiconductor leaders Nvidia (NVDA) vs. AMD, beverage companies Coca-Cola (KO) vs. Pepsi (PEP), and electric vehicle makers Tesla (TSLA) vs. Rivian (RIVN).
Why Compare Stocks?
Comparing stocks helps investors identify which companies offer the best value, growth potential, and risk-adjusted returns. By analyzing multiple stocks side by side, you can better understand relative valuations, competitive advantages, and market positioning before making investment decisions.